What's breaking now, across thousands of outlets.
(RTTNews) - Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate of decline in forced vital capacity (FVC).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
[Economy] : The local stock market extended its losses on Tuesday, with the benchmark KOSPI plunging more than six percent and sinking below the six-thousand-point mark.
Tenor 1-day Notified Amount (in ₹ crore) 1,50,000 Total amount of offers received (in ₹ crore) 71,580 Amount accepted (in ₹ crore) 71,580 Cut off Rate (%) 5.49 Weighted Average Rate (%) 5.49 Partial…
Shinhan Financial Group Inc., a major banking group, has decided to take over a midsize non-life insurer for 693 billion won ($518 million) to diversify its business portfolio, industry sources said…
Abu Dhabi Islamic Bank (ADIB), a leading financial institution, today announced the key dates and details for its upcoming rights issue, following shareholder approval of the Bank’s capital increase…
The body led by Kristalina Georgieva raises by four tenths the growth of the Spanish economy in 2026, but increases by 7 tenths its inflation forecast, to 3.7%.
(RTTNews) - Nokia Oyj (NOK), a telecommunications and network technology company, on Tuesday announced that it has signed a definitive agreement to sell its Enterprise Campus Edge business to…
